Bosslet K - Search Results

1

Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.

Bauss F, Lechmann M, Krippendorff BF, Staack R, Herting F, Festag M, Imhof-Jung S, Hesse F, Pompiati M, Kollmorgen G, da Silva Mateus Seidl R, Bossenmaier B, Lau W, Schantz C, Stracke JO, Brinkmann U, Onda M, Pastan I, Bosslet K, Niederfellner G. Bauss F, et al. Among authors: bosslet k. Mol Oncol. 2016 Oct;10(8):1317-29. doi: 10.1016/j.molonc.2016.07.003. Epub 2016 Jul 14. Mol Oncol. 2016. PMID: 27507537 Free PMC article.

2

Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers.

Alewine C, Xiang L, Yamori T, Niederfellner G, Bosslet K, Pastan I. Alewine C, et al. Among authors: bosslet k. Mol Cancer Ther. 2014 Nov;13(11):2653-61. doi: 10.1158/1535-7163.MCT-14-0132. Epub 2014 Sep 19. Mol Cancer Ther. 2014. PMID: 25239937 Free PMC article.

3

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.

Brünker P, Wartha K, Friess T, Grau-Richards S, Waldhauer I, Koller CF, Weiser B, Majety M, Runza V, Niu H, Packman K, Feng N, Daouti S, Hosse RJ, Mössner E, Weber TG, Herting F, Scheuer W, Sade H, Shao C, Liu B, Wang P, Xu G, Vega-Harring S, Klein C, Bosslet K, Umaña P. Brünker P, et al. Among authors: bosslet k. Mol Cancer Ther. 2016 May;15(5):946-57. doi: 10.1158/1535-7163.MCT-15-0647. Epub 2016 Apr 1. Mol Cancer Ther. 2016. PMID: 27037412

4

Tumor-selective prodrug activation by fusion protein-mediated catalysis.

Bosslet K, Czech J, Hoffmann D. Bosslet K, et al. Cancer Res. 1994 Apr 15;54(8):2151-9. Cancer Res. 1994. PMID: 8174122

5

Fusion protein mediated prodrug activation (FMPA) in vivo.

Bosslet K, Czech J, Seemann G, Monneret C, Hoffmann D. Bosslet K, et al. Cell Biophys. 1994;24-25:51-63. doi: 10.1007/BF02789215. Cell Biophys. 1994. PMID: 7736540

6

Recombinant monoclonal antibodies in tumor therapy.

Seemann G, Bosslet K, Sedlacek HH. Seemann G, et al. Among authors: bosslet k. Behring Inst Mitt. 1990 Dec;(87):33-47. Behring Inst Mitt. 1990. PMID: 2096819 Review.

7

Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.

Gao J, Chesebrough JW, Cartlidge SA, Ricketts SA, Incognito L, Veldman-Jones M, Blakey DC, Tabrizi M, Jallal B, Trail PA, Coats S, Bosslet K, Chang YS. Gao J, et al. Among authors: bosslet k. Cancer Res. 2011 Feb 1;71(3):1029-40. doi: 10.1158/0008-5472.CAN-10-2274. Epub 2011 Jan 18. Cancer Res. 2011. PMID: 21245093

8

Elucidation of the mechanism enabling tumor selective prodrug monotherapy.

Bosslet K, Straub R, Blumrich M, Czech J, Gerken M, Sperker B, Kroemer HK, Gesson JP, Koch M, Monneret C. Bosslet K, et al. Cancer Res. 1998 Mar 15;58(6):1195-201. Cancer Res. 1998. PMID: 9515805

9

Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.

Florent JC, Dong X, Gaudel G, Mitaku S, Monneret C, Gesson JP, Jacquesy JC, Mondon M, Renoux B, Andrianomenjanahary S, Michel S, Koch M, Tillequin F, Gerken M, Czech J, Straub R, Bosslet K. Florent JC, et al. Among authors: bosslet k. J Med Chem. 1998 Sep 10;41(19):3572-81. doi: 10.1021/jm970589l. J Med Chem. 1998. PMID: 9733483

10

Application of the ADEPT strategy to the MDR resistance in cancer chemotherapy.

Desbene S, Van HD, Michel S, Tillequin F, Koch M, Schmidt F, Florent JC, Monneret C, Straub R, Czech J, Gerken M, Bosslet K. Desbene S, et al. Among authors: bosslet k. Anticancer Drug Des. 1999 Apr;14(2):93-106. Anticancer Drug Des. 1999. PMID: 10405636

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

78 results

Search Page